Division of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA; Division of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, USA; Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
Division of Cardiovascular Medicine, Ohio State University, Columbus, OH, USA.
Glob Heart. 2018 Mar;13(1):13-18. doi: 10.1016/j.gheart.2018.01.002. Epub 2018 Mar 5.
Non-ST-segment elevation myocardial infarction (NSTEMI) comprises the majority of MI worldwide, yet mortality remains high. Management of NSTEMI is relatively delayed and heterogeneous compared with the "time is muscle" approach to ST-segment elevation MI, though it is unknown to what extent comorbid conditions drive NSTEMI mortality.
We sought to quantify mortality due to MI versus comorbid conditions in patients with NSTEMI.
Participants of the ARIC (Atherosclerosis Risk in Communities) study cohort ages 45 to 64 years, who developed incident NSTEMI were identified and incidence-density matched to participants who did not experience an MI by age group, sex, race, and study community. We estimated hazard ratios for all-cause mortality, comparing those who developed NSTEMI to those who did not experience an MI.
ARIC participants with incident NSTEMI were more likely at baseline to be smokers, have diabetes and renal dysfunction, and take blood pressure or cholesterol-lowering medications than were participants who did not have an MI. Over one-half of participants experiencing NSTEMI died over a median follow-up of 8.4 years; incident NSTEMI was associated with 30% higher risk of mortality after adjusting for comorbid conditions (hazard ratio: 1.30; 95% confidence interval: 1.11 to 1.53).
NSTEMI confers a significantly higher mortality hazard beyond what can be attributed to comorbid conditions. More consistent and effective strategies are needed to reduce mortality in NSTEMI amid comorbid conditions.
非 ST 段抬高型心肌梗死(NSTEMI)占全球心肌梗死的大多数,但死亡率仍然很高。与 ST 段抬高型心肌梗死的“时间就是心肌”方法相比,NSTEMI 的管理相对延迟且存在异质性,尽管尚不清楚合并症在多大程度上导致了 NSTEMI 的死亡率。
我们旨在量化 NSTEMI 患者因心肌梗死和合并症导致的死亡率。
从 ARIC(社区动脉粥样硬化风险)研究队列中确定年龄在 45 至 64 岁之间发生新发 NSTEMI 的参与者,并按年龄组、性别、种族和研究社区与未发生心肌梗死的参与者进行年龄密度匹配。我们比较了发生 NSTEMI 的患者和未发生心肌梗死的患者,估计了全因死亡率的风险比。
与未发生心肌梗死的参与者相比,发生 NSTEMI 的 ARIC 参与者在基线时更有可能吸烟、患有糖尿病和肾功能障碍,并且更有可能服用降血压或降胆固醇药物。超过一半的经历 NSTEMI 的患者在中位数为 8.4 年的随访期间死亡;在调整了合并症后,NSTEMI 与 30%更高的死亡率风险相关(风险比:1.30;95%置信区间:1.11 至 1.53)。
NSTEMI 导致的死亡率风险明显高于合并症所归因的死亡率风险。需要更一致和有效的策略来降低 NSTEMI 合并症患者的死亡率。